A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

2012 ◽  
Vol 13 (6) ◽  
pp. 505-509 ◽  
Author(s):  
Edward B. Garon ◽  
Dachuang Cao ◽  
Ekaterine Alexandris ◽  
William J. John ◽  
Sergey Yurasov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Disease Progression ◽  
Study Design ◽  
Stage Iv ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Double Blind ◽  
Phase Iii Study

Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer

2013 ◽  
Vol 3 (1) ◽  
pp. 29-35 ◽  
Author(s):  
Michael Boyer ◽  
Pasi Antero Jänne ◽  
Tony Mok ◽  
Kenneth O’Byrne ◽  
Luis Paz-Ares ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Study Design ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Double Blind ◽  
Phase Iii Study
Sign in / Sign up

Export Citation Format

Share Document